Organon & Co. Stock News

Benjamin Graham is known for developing a fairly complex set of rules and formulas to determine a stock's intrinsic value. In his final year, Graham offered a much simpler means of finding value, but

Organon's (OGN) CEO Kevin Ali on Q2 2021 Results - Earnings Call Transcript

Organon's (OGN) earnings and revenues beat estimates in the second quarter of 2021. Stock up in pre-market trading.

Merck & Co Inc on Thursday reported a 49% fall in second-quarter profit after it spun off its women's health and biosimilar assets into Organon in June.

GuruFocus' Most Broadly Held model portfolio consists of the 25 stocks that have the highest number of guru owners, rebalanced annually.

JERSEY CITY, N.J. & GENEVA, Switzerland--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), a global women's health company and ObsEva (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company dedicated to

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon To Report Fiscal Q2 Results and Host Conference Call on August 12, 2021

Organon: Merck Spin-Off's Shares Hard To Resist At Current Price

On the surface, these companies seem like underpriced investments, but look a little closer and there's a good reason to stay away.

Neither healthcare stock has performed well so far this year.

Organon's low growth, lack of strong catalysts and likely average future dividend combine to make OGN stock unattractive. The post Stay Away From Low-Growth Organon appeared first on InvestorPlace.

Don't think of Merck spinoff Organon as a research engine. The new pharmaceutical stock is a pure-play commercial entity.

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon Recommends Stockholders Reject Below-Market Mini-Tender Offer by TRC Capital Investment Corporation

Although spinoffs of well-known organizations have been known to outperform, you'll want to examine OGN stock carefully. The post Motivation Really Matters When It Comes to Organon appeared first on I

The market is trading at some of the most overvalued levels in 20 years. Over the next five years, analysts expect 5% CAGR returns from the S&P 500. That's about 1/3 of what investors have enjoyed for